
Keywords: آنزیم وابسته به ایمنی اسیاب محل آزمون; ELISpot; enzyme-linked immunosorbent spot assay; FDA; Food and Drug Administration; HbA1c; hemoglobin A1c; NOD; non-obese diabetic; pMHC; peptide-MHC; SoC; standard of care; T1D; Type 1 diabetes; Type 1 diabetes; Immunotherapy; Biomarkers;